Evaluation of glycated albumin levels in tears and saliva as a marker in patients with diabetes mellitus
Evaluation of glycated albumin levels in tears and saliva as a marker in patients with diabetes mellitus
复制标题
DOI：
10.1016/j.diabres.2023.110637
复制
发表时间：
2023-05-05
影响因子：
5.1
通讯作者：
Kubota, Naoto
中科院分区：
文献类型：
--
作者：
Aihara, Masakazu;Jinnouchi, Hideaki;Kubota, Naoto
目的：糖化白蛋白（GA）是一种生物标志物，其水平反映了过去2周的血糖控制状态。为了开发一种非侵入性的方法来评估糖尿病患者的血糖控制，我们调查了测量的GA水平的眼泪和唾液，这可以收集noninvasions.Methods：眼泪和唾液样本收集了48名糖尿病患者。结果：泪液和唾液中的GA含量与血液中的GA含量呈显著正相关（P <0.001），唾液中的GA含量与血液中的GA含量呈显著正相关（P < 0.001）。多元回归分析显示，即使调整BMI、年龄和肾病分期后，这些相关性仍保持不变（P < 0.001）。结论：泪液和唾液中的GA水平作为糖尿病相关的生物标志物，可以无创地进行检测。由于这种测量可以非侵入性地进行，并且与更具侵入性的手指针刺方法相比不那么频繁，因此预计在侵入性和成本效益方面减轻糖尿病患者的负担。将来，我们希望在考虑临床成本效益的同时验证定期GA测量对血糖控制的影响。
Aims: Glycated albumin (GA) is a biomarker, whose level reflects glycemic control status over the previous 2 weeks. To develop a non-invasive method for evaluating glycemic control in people with diabetes mellitus, we investigated the measurement of GA levels in tears and saliva, which could be collected noninvasively.Methods: Tear and saliva samples were collected from 48 participants with diabetes mellitus. The GA levels in the tear and saliva specimens were measured by Liquid Chromatography-Mass Spectrometry (LC-MS/MS).Results: GA levels in both tear and saliva samples were significantly correlated with the GA levels in the blood (P < 0.001). Multiple regression analysis revealed that these correlations were maintained even after adjustments for the BMI, age, and nephropathy stage (P < 0.001).Conclusion: GA levels in tear and saliva specimens, as diabetes-related biomarkers, can be measured non-invasively. Since this measurement can be performed noninvasively and not as frequently as compared with the more invasive finger prick method, it is expected to reduce the burden on people with diabetes in terms of both the invasiveness and cost-effectiveness. In the future, we would like to verify the effect of regular GA measurement on the glycemic control while considering the clinical cost-effectiveness.